Henan Lingrui Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Henan Lingrui Pharmaceutical Co Ltd cash flow-to-debt ratio. Henan Lingrui Pharmaceutical Co Ltd (600285) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of CN¥140.12 Million could theoretically repay 0% of its total liabilities (CN¥2.47 Billion) in one year. Check Henan Lingrui Pharmaceutical Co Ltd (600285) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
Cash flow-to-debt ratio of Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2025. Historical debt coverage capacity for Henan Lingrui Pharmaceutical Co Ltd across 27 annual periods. Check Henan Lingrui Pharmaceutical Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Henan Lingrui Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (1999–2025)
Henan Lingrui Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 1999 to 2025. Year-by-year debt coverage analysis for Henan Lingrui Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 600285 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | CN¥553.88 Million | CN¥2.20 Billion | ▼ -44.3% |
| 2024 | 0.45x | CN¥875.86 Million | CN¥1.94 Billion | ▲ +9.7% |
| 2023 | 0.41x | CN¥813.43 Million | CN¥1.97 Billion | ▼ -11.8% |
| 2022 | 0.47x | CN¥834.91 Million | CN¥1.79 Billion | ▼ -16.7% |
| 2021 | 0.56x | CN¥845.69 Million | CN¥1.51 Billion | ▲ +41.5% |
| 2020 | 0.40x | CN¥450.53 Million | CN¥1.14 Billion | ▼ -3.5% |
| 2019 | 0.41x | CN¥450.15 Million | CN¥1.10 Billion | ▼ -4.3% |
| 2018 | 0.43x | CN¥436.25 Million | CN¥1.02 Billion | ▲ +347.3% |
| 2017 | 0.10x | CN¥105.97 Million | CN¥1.10 Billion | ▲ +32.0% |
| 2016 | 0.07x | CN¥63.26 Million | CN¥869.35 Million | ▼ -54.3% |
| 2015 | 0.16x | CN¥156.82 Million | CN¥984.58 Million | ▲ +17.1% |
| 2014 | 0.14x | CN¥124.32 Million | CN¥913.70 Million | ▼ -29.1% |
| 2013 | 0.19x | CN¥127.27 Million | CN¥663.24 Million | ▲ +642.7% |
| 2012 | 0.03x | CN¥15.43 Million | CN¥597.36 Million | ▼ -66.6% |
| 2011 | 0.08x | CN¥40.49 Million | CN¥524.02 Million | ▲ +1056.7% |
| 2010 | -0.01x | CN¥-3.95 Million | CN¥489.25 Million | ▼ -102.3% |
| 2009 | 0.35x | CN¥132.61 Million | CN¥378.52 Million | ▲ +235.4% |
| 2008 | 0.10x | CN¥43.72 Million | CN¥418.55 Million | ▲ +137.4% |
| 2007 | 0.04x | CN¥15.99 Million | CN¥363.31 Million | ▼ -35.6% |
| 2006 | 0.07x | CN¥26.76 Million | CN¥392.03 Million | ▼ -19.9% |
| 2005 | 0.09x | CN¥33.43 Million | CN¥392.44 Million | ▼ -13.8% |
| 2004 | 0.10x | CN¥35.51 Million | CN¥359.36 Million | ▲ +20.3% |
| 2003 | 0.08x | CN¥23.79 Million | CN¥289.65 Million | ▼ -66.8% |
| 2002 | 0.25x | CN¥69.41 Million | CN¥281.00 Million | ▲ +1048.4% |
| 2001 | 0.02x | CN¥3.41 Million | CN¥158.59 Million | ▼ -37.6% |
| 2000 | 0.03x | CN¥3.66 Million | CN¥106.33 Million | ▼ -19.1% |
| 1999 | 0.04x | CN¥4.81 Million | CN¥112.94 Million | — |